Bausch Health resolves IP litigation with Teva

Canadian pharmaceutical company Bausch Health and generics maker Teva have resolved their dispute over Apriso (mesalazine), a drug used to treat ulcerative colitis and Crohn's disease.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Bausch targets India-based firm over IBS drug generic

20 June 2023 Pharma giant claims infringement of two patents | Hyderabad-based rival’s letter offering details of proposed generic allegedly lacked certain required details.

Big Pharma

Bausch settles $300m antitrust case over diabetes drug price hikes

13 September 2021 Canadian pharma firm Bausch Health has agreed to settle an antitrust suit where it was accused of holding an illegal monopoly on the diabetes drug Glumetza.

Americas

US judge dismisses attorney’s ‘opportunistic’ whistleblower suit

14 May 2020 A Californian judge has thrown out an attorney’s whistleblower lawsuit alleging Bausch Health Companies fraudulently obtained a patent for its ulcerative colitis drug Apriso.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Bausch Health resolves IP litigation with Teva

More on this story

Editor's picks

Editor's picks

More features